Preclinical and clinical pharmacology of cerivastatin

American Journal of Cardiology

Volumn 82, Issue 4 B, 1998, Pages 18J-25J

  Bischoff, Hilmar ^a   Heller, Allen H ^b  

^a BAYER AG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LOW DENSITY LIPOPROTEIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ATHEROSCLEROSIS; CHOLESTEROL METABOLISM; CONFERENCE PAPER; DOG; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; ENZYME INHIBITION; HYPOLIPEMIA; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RABBIT; RAT;

EID: 0032572716     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00433-0     Document Type: Conference Paper

References (30)

1. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res. 33:1992;1569-1582.
2. Bischoff H., Angerbauer R., Boberg M., Schmidt D. Cerivastatin high enzyme affinity and active metabolites contribute to its high pharmacological activity . Atherosclerosis. 130:(suppl):1997;25.
3. Bischoff H, Petzinna D. BAY W 6228: A new generation HMG-CoA reductase inhibitor II. Inhibition of cholesterol synthesis in rats and dogs. (Abstr.) XI International Symposium on Drugs Affecting Lipid Metabolism. Florence (Italy), May 1992.
4. Bischoff H., Angerbauer R., Bender J., Bischoff E., Faggiotto A., Petzinna D., Pfitzner J., Porter M.C., Schmidt D., Thomas G. Cerivastatin pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor . Atherosclerosis. 135:1997;119-130.
5. Hayashi K., Nashiro M., Kurushima H., Kuga Y., Nomura S., Ohkura Y., Ohtani H., Kurokawa J., Tanaka K., Shingu T., Kambe M., Kajiyama G. Effect of (+)-3R, 5S-sodium erythro-(E)-7-[4-(4-fluorphenyl)-2,6-diisopropyl-5-methoxymethyl-pyrid-3-yl]-3, 5-dihydrox-hept-6-enoate (BAY w 6228), a new inhibitor of HMG-CoA reductase, on the induction of hepatic LDL receptor and plasma cholesterol level. (Abstr.) Atherosclerosis. 109:1994;255.
6. Corsini A., Arnaboldi L., Raiteri M., Quarato P., Faggiotto A., Paoletti R., Fumagalli R. Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY W 6228) on migration, proliferation and cholesterol synthesis in arterial myocytes. Pharmacol Res. 33:1996;55-61.
7. Faggiotto A. BAY w 6228: a new generation HMG-CoA reductase inhibitor. VI. Lipid lowering and anti-atherosclerotic activity in hypercholesterolemic rabbits. (Abstr.) XI International Symposium on Drugs Affecting Lipid Metabolism. Florence (Italy), May 1992;70.
8. Ritter W., Frey R., Krol G., Kuhlmann J. Single dose pharmacokinetics of rivastatin, a novel HMG-CoA reductase inhibitor. (Abstr. No. 155) Naunyn Schmiedebergs Arch Pharmacol. 347:(suppl):1993;R39.
9. Ritter W., Frey R., Krol G., Kuhlmann J. Rivastatin single dose pharmacokinetics. (Abstr. No. PIII-14) Clin Pharmacol Ther. 53:1993;210.
10. Frey R., Mazzu A., Ritter W., Heller A.H., Kuhlmann J. Safety and tolerability of rivastatin, a novel HMG-CoA reductase inhibitor in phase I-single dose studies. (Abstr.) Naunyn Schmiedebergs Arch Pharmacol. 33:(suppl):1993;119.
11. Azuma J. Phase I study of an antihyperlipidaemic BAY W 6228 (cerivastatin sodium) (1) results of single administration studies in healthy adult male volunteers . Jpn Pharmacol Ther. 24:(suppl 9):1996;29-36.
12. Azuma J. Phase I study of antihyperlipidaemic BAY W 6228 (cerivastatin sodium) (2) results of multiple administration studies in healthy adult male volunteers . Jpn Pharmacol Ther. 24:(suppl 9):1996;37-53.
13. Mazzu A.L., Lettieri J., Kaiser L., Frey R., Heller A.H. Ascending multiple dose safety, tolerability and pharmacodynamics of rivastatin in humans. (Abstr. No. PIII-95) Clin Pharmacol Ther. 53:1993;230.
14. Stein E.A., Sprecher D., Allenby K.S., Tosiello R.L., Whalen E., Ripa S.R. Cerivastatin, a new potent synthetic HMG-CoA reductase inhibitor effect of 0.2 mg daily in subjects with primary hypercholesterolemia . J Cardiovasc Pharmacol Ther. 2:1997;7-16.
15. Stein EA, Isaacsohn J, Stolz R, Mazzu A, Liu MC, Lane C, Heller AH. Efficacy and safety of 0.8 mg dosage of cerivastatin, a novel HMG-CoA reductase inhibitor. (Abstr. 254470) 47th Scientific Session of the American College of Cardiology, 1998.
16. Lettieri J., Krol G., Mazzu A., Shah A., Falk R., Beck C. Effect of age and gender on the steady-state pharmacokinetics of rivastatin. (Abstr. No. PPDM 8159) Pharm Res. 10:(suppl):1993;S338.
17. Mazzu A., Lettieri J., Heller A.H. Pharmacokinetics of cerivastatin administration with and without food in the morning and evening. (Abstr. No. 111) Atherosclerosis. 130:(suppl):1997;S29.
18. Mazzu A., Lettieri J., Hogan C., Kaiser J., Heller A.H. A multiple-dose study on the safety and pharmacokinetics of cerivastatin in young and elderly male volunteers. (Abstr. No. 112) Atherosclerosis. 130:(suppl):1997;S29.
19. Stein E.A., Isaacsohn J., Mazzu A., Lettieri J., Heller A.H. Pharmacokinetics, safety and tolerability of multiple-dose cerivastatin in males and females A double-blind study . (Abstr. No. 126) Atherosclerosis. 130:(suppl):1997;33.
20. 2-antagonist cimetidine on the pharmacokinetics of cerivastatin. Int J Clin Pharmacol Ther. 35:1997;261-264.
21. Mück W., Ritter W., Frey R., Wetzelsberger N., Lücker P.W., Kuhlmann J. Influence of cholestyramine on the pharmacokinetics of cerivastatin. Int J Clin Pharmacol Ther. 35:1997;250-254.
22. Lettieri J., Krol G., Mazzu A., Fiebach M., Heller A.H. Lack of pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxin. Atherosclerosis. 130:(suppl):1997;S29-A109.
23. Schall R., Müller F.O., Hundt H.K.L., Ritter W., Duursema L., Groenewoud G., Middle M.V. No pharmacokinetic or pharmacodynamic interaction between rivastatin and warfarin. J Clin Pharmacol. 35:1995;306-313.
24. Mück W., Ochmann K., Unger S., Kuhlmann J. Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Eur J Clin Pharmacol. 53:1998;469-473.
25. Steinke W., Yamashitas Tabei M., Ahr H.J., Beckermann B., Domdey-Bette A., Göller G., Schwarz T., Siefert H.M. Cerivastatin, a new inhibitor of HMG-CoA reductase pharmacokinetics in rats and dogs . Jpn Pharmacol Ther. 24:1996;S1217-S1237.
26. Boberg M., Angerbauer R., Kanhai W., Karl W., Kern A., Ploschke J., Radtke M. Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolite pathways and of cytochrome P450 isozymes involved. Drug Metab Dispos. 25:1997;321-331.
27. Data on file, Bayer Corporation, West Haven, CT.
28. Kanhai W., Kern A., Nowak K., Radtke M., Boberg M. Cerivastatin identification of human CYP450 isoforms involved in the biotransformation of the drug and two active metabolites . (Abstr. No. 217) ISSX-Proceedings. 12:1997;109.
29. Krause B.R., Newton R.S. Lipid-lowering activity of atorvastatin and lovastatin in rodent species triglyceride-lowering in rats correlates with efficacy in LDL animal models . Atherosclerosis. 117:1995;237-244.
30. Vaughan C.J., Murphy M.B., Buckley B.M. Statins do more than just lower cholesterol. Lancet. 348:1996;1079-1082.